Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-06 |
2024-03 |
-0.76 |
-0.78 |
-0.02 |
-2.63% |
2024-04-04 |
2023-12 |
-0.75 |
N/A |
N/A |
N/A |
2023-11-09 |
2023-09 |
-0.78 |
N/A |
N/A |
N/A |
2023-11-09 |
2023-09 |
-0.78 |
-0.7 |
0.08 |
10.26% |
2023-08-09 |
2023-06 |
-0.73 |
N/A |
N/A |
N/A |
2023-08-09 |
2023-06 |
-0.73 |
-0.7 |
0.03 |
4.11% |
Date |
Firm |
Action |
From |
To |
2023-10-03 |
Needham |
Upgrade |
Buy |
Buy |
2023-09-26 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-09-26 |
Needham |
Upgrade |
Buy |
Buy |
2023-09-14 |
Needham |
Upgrade |
Buy |
Buy |
2023-08-28 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-21 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
Date |
Name |
Relation |
Quantity |
Description |
2024-01-22 |
CHEUNG LILY |
Officer |
26.80K |
Stock Award(Grant) |
2024-01-22 |
COULIE BERNARD J |
Chief Executive Officer |
853.85K |
Stock Award(Grant) |
2024-05-01 |
CUMMINGS KEITH LAMONT |
Chief Financial Officer |
271.71K |
Conversion of Exercise of derivative security |
2020-06-04 |
HOWES BARBARA |
Officer |
24.80K |
Conversion of Exercise of derivative security |
2020-06-04 |
HUH HOYOUNG |
Director |
0.00 |
Conversion of Exercise of derivative security |
2024-01-22 |
HULL HANS P |
Officer |
248.36K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Blackrock Inc. |
4.41M |
79.85M |
7.37% |
2023-06-29 |
FMR, LLC |
4.24M |
76.87M |
7.09% |
2023-06-29 |
Deep Track Capital, Lp |
4.05M |
73.39M |
6.77% |
2023-06-29 |
Laurion Capital Management, LP |
3.16M |
57.23M |
5.28% |
2023-06-29 |
Chi Advisors Llc |
3.12M |
56.48M |
5.21% |
2023-06-29 |
Price (T.Rowe) Associates Inc |
2.97M |
53.83M |
4.97% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.55M |
28.04M |
2.59% |
2023-08-30 |
Fidelity Growth Company Fund |
1.34M |
22.65M |
2.24% |
2023-06-29 |
Price (T.Rowe) New Horizons Fund |
1.30M |
23.57M |
2.17% |
2023-08-30 |
iShares Russell 2000 ETF |
1.29M |
21.72M |
2.15% |
2023-06-29 |
Smallcap World Fund |
912.47K |
16.53M |
1.52% |
2023-06-29 |
Vanguard Extended Market Index Fund |
595.21K |
10.79M |
0.99% |
Split |
Date |
0.125 : 1 |
2000-12-04 |